secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2026-10-20T20:57:30+00:00
Accession:  0001193125-26-426811
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Inhibikase adds Amgen vet Scott Wasserman to board; Dennis Berman resigns
-------------------------------------------------------------------------

- Scott M. Wasserman, MD, appointed Class III director effective October 19, 2026, serving until the 2029 annual meeting; he joins the Compensation Committee.
- Wasserman gets an initial grant of non-qualified options for up to 310,000 IKT shares plus cash compensation under the non-employee director policy.
- Wasserman is CMO of Kailera Therapeutics; at Amgen he led global development and approvals of Repatha, Evenity and Aimovig.
- Dennis Berman resigned the same day as director and Compensation Committee chair and Audit Committee member; no disagreement cited.
- Chairman Amit Munshi cited Wasserman's expertise as Inhibikase advances the global Phase 3 IMPROVE-PAH study of oral IKT-001 for PAH.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312526426811/0001193125-26-426811-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312526426811/d190975d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-426811

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer